Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 1 of 1 entries
View as:
Phase: N/A
Priority: Normal
Start: 11/15/23
End: 04/22/24
Due: 04/22/25
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| IMM60 and Pembrolizumab in Melanoma and NSCLC | NCT05709821 | iOx Therapeutics | user2@example.com | None | 2023-11-15 | 2024-04-22 | 2025-04-22 | - | - | 2025-07-14 |